Coefficient

• Anthropic anunció la adquisición de Coefficient Bio, una startup de IA con sede en EE. UU. especializada en modelado biológico, el 27 de abril de 2026. • El acuerdo tiene como objetivo integrar las herramientas de IA de diseño de proteínas de Coefficient con los modelos Claude de Anthropic para aplicaciones avanzadas en el descubrimiento de fármacos. • Este movimiento posiciona a Anthropic en el competitivo espacio de la biotecnología de IA en medio de inversiones crecientes, acelerando potencialmente los avances en medicina personalizada.

• Anthropic expanded its AI strategy by acquiring AI drug discovery startup Coefficient Bio for approximately $400 million and launching a political action committee to influence AI regulation. • The company is also seeing surging investor demand for its shares amid tightening AI infrastructure supply and growing market appetite. • These moves position Anthropic to shape policy, enter life sciences, and capitalize on demand for leading AI technologies in the US.

• Anthropic acquired Coefficient Bio, a startup founded eight months ago with fewer than 10 employees, for roughly $400 million in shares, despite it having no product or revenue. • The platform uses AI for pharmaceutical tasks like drug research planning and identifying new drug opportunities, positioning Anthropic's models for scientific discovery in life sciences. • This bet signals a strategic push into AI-driven biotech, potentially accelerating drug development amid growing competition in applied AI verticals.

• Anthropic acquired startup Coefficient Bio for more than $400 million to bolster its AI capabilities amid recent challenges like a source code leak. • The deal follows Anthropic's npm packaging error exposing Claude Code's source code, including memory architecture and model roadmap. • This acquisition strengthens Anthropic's position despite setbacks, potentially aiding future developments in autonomous AI features.